Pair Name	Evodiamine, Doxorubicin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BIRC2	hsa329
	Down-regulation	Expression	BIRC5	hsa332
	Up-regulation	Activity	CASP7	hsa840
	Up-regulation	Activity	CASP9	hsa842
	Down-regulation	Expression	KRAS	hsa3845
	Down-regulation	Phosphorylation	MAP2K7	hsa5609
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Up-regulation	Activity	PARP1	hsa142
	Down-regulation	Expression	XIAP	hsa331
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
Result	Our results indicated that EVO enhanced the apoptotic action of DOX by inhibiting the Ras/MEK/ERK cascade and the expression of IAPs without inhibiting the expression and activity of P-glycoprotein (P-gp). Taken together, our data indicate that EVO, a natural product, may be useful applied alone or in combination with DOX for the treatment of resistant breast cancer.